Drug Interactions With Phosphodiesterase-5 Inhibitors Used for the Treatment of Erectile Dysfunction or Pulmonary Hypertension

2010/07/06 by Bryan G. Schwartz, Robert A. Kloner · 122 citations
Medicine · #Cardiology #Cardiovascular Issues in Pregnancy #Drug #Enzyme #Erectile dysfunction #Heart Failure Treatment and Management #Intensive care medicine #Internal medicine #Medicine #Pharmacology #Phosphodiesterase #Pulmonary Hypertension Research and Treatments #Pulmonary hypertension #Sildenafil #Tadalafil #Vasodilation #Vasodilator agents #cGMP-specific phosphodiesterase type 5

paper · doi:10.1161/circulationaha.110.944603

published in Circulation 122(1), 88-95 (Lippincott Williams & Wilkins)

openalex publication_date 2010/07/06 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/27

Cited by

• Neutrophil-hitchhiking luteolin-loaded nanozyme for vein graft restenosis
• Adverse Events Associated With Coprescription of Phosphodiesterase Type 5 Inhibitors and Oral Organic Nitrates in Male Patients With Ischemic Heart Disease
• Nonantithrombotic medical options in acute coronary syndromes: old agents and new lines on the horizon. [europepmc]
• Phosphodiesterase 8a supports HIV-1 replication in macrophages at the level of reverse transcription. [europepmc]
• Understanding and Managing Erectile Dysfunction in Patients Treated for Cancer. [europepmc]
• Drug-related problems in patients with erectile dysfunctions and multiple comorbidities. [europepmc]
• Pharmacokinetics of Sildenafil in Patients with a Left Ventricular Assist Device: A Word of Caution. [europepmc]
• Dermatologic care for lesbian, gay, bisexual, and transgender persons: Epidemiology, screening, and disease prevention. [europepmc]
• Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond. [europepmc]
• Pharmacokinetic parameters of ifosfamide in mouse pre-administered with grapefruit juice or naringin. [europepmc]
• Are There Adverse Events after the Use of Sexual Enhancement Nutrition Supplements? A Nationwide Online Survey from Japan. [europepmc]
• The effects of sildenafil on ciliary beat frequency in patients with pulmonary non-tuberculous mycobacteria disease: phase I/II trial. [europepmc]
• Use of "Poppers" among Adults in the United States, 2015-2017. [europepmc]
• Immediate post-operative PDE5i therapy improves early erectile function outcomes after robot assisted radical prostatectomy (RARP). [europepmc]
• Analysis of integrated clinical safety data of tadalafil in patients receiving concomitant antihypertensive medications. [europepmc]
• Influence of methylxanthines isolated from Bancha green tea on the pharmacokinetics of sildenafil in rats. [europepmc]
• Erectile Dysfunction: Pharmacological Pathways with Understudied Potentials. [europepmc]
• Sexual health and treatment-related sexual dysfunction in sexual and gender minorities with prostate cancer. [europepmc]
• Heart Failure and Erectile Dysfunction: a Review of the Current Evidence and Clinical Implications. [europepmc]
• Best Practices in Pharmacotherapy for Acute Coronary Syndromes. [europepmc]
• Erectile dysfunction associated with prostate cancer treatment and therapeutic advances: a narrative review. [europepmc]
• Depression in Pulmonary Hypertension: A Systematic Review of Clinical Outcomes, Treatment Interactions, and Emerging Technologies. [europepmc]
• ACVRL1 variation-induced hereditary hemorrhagic telangiectasia presenting with pulmonary arterial hypertension: clinical and genetic analyses of three case studies. [europepmc]
• Safety profile and signal detection of tadalafil: a real-world analysis based on the Food and Drug adverse event reporting system. [europepmc]
• Large language models for post-discharge follow-up in erectile dysfunction care: a narrative review. [europepmc]